公开(公告)号：WO2009123967A1

公开(公告)日：2009-10-08

申请号：PCT/US2009/038775

申请日：2009-03-30

Applicant: ABBOTT LABORATORIES ,  LIU, Huaqing ,  DRIZIN, Irene ,  KOENIG, John, R. ,  COWART, Marlon, D. ,  ZHAO, Chen ,  WAKEFIELD, Brian, D. ,  BLACK, Lawrence, A. ,  ALTENBACH, Robert, J.

Inventor： LIU, Huaqing ,  DRIZIN, Irene ,  KOENIG, John, R. ,  COWART, Marlon, D. ,  ZHAO, Chen ,  WAKEFIELD, Brian, D. ,  BLACK, Lawrence, A. ,  ALTENBACH, Robert, J.

IPC: C07D239/84 ,  C07D403/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  A61K31/517 ,  A61P11/06

CPC classification number: C07D401/04 ,  C07D239/70 ,  C07D239/84 ,  C07D239/88 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10

Abstract: Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Abstract translation: 本文描述了大环嘧啶化合物，包含这些化合物的组合物，制备化合物的方法，以及使用这些化合物和组合物治疗和预防疾病，病症和病症进展的方法。

公开(公告)号：WO1998024791A1

公开(公告)日：1998-06-11

申请号：PCT/US1997022279

申请日：1997-12-04

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MEYER, Michael, D. ,  ALTENBACH, Robert, J. ,  BASHA, Fatima ,  CARROLL, William, A. ,  DRIZIN, Irene ,  KERWIN, James, F. ,  WENDT, Michael, D. ,  HAIGHT, Anthony, R. ,  ZHANG, Weijiang

IPC: C07D491/04

CPC classification number: C07D491/04

Abstract: The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are alpha -1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are alpha -1 antagonist compositions and a method for antagonizing alpha -1 adrenoreceptors and treating BPH.

Abstract translation: 本发明涉及式（I）化合物及其药学上可接受的盐，其中W是双环杂环体系。 该化合物是α-1肾上腺素能拮抗剂，可用于治疗BPH; 还公开了α-1拮抗剂组合物和拮抗α-1肾上腺素受体并治疗BPH的方法。

公开(公告)号：WO1996022992A1

公开(公告)日：1996-08-01

申请号：PCT/US1996000072

申请日：1996-01-11

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MEYER, Michael, D. ,  ALTENBACH, Robert, J. ,  BASHA, Fatima, Z. ,  CARROLL, William, A. ,  DRIZIN, Irene ,  KERWIN, James, F., Jr. ,  LEBOLD, Suzanne, A. ,  LEE, Edmund, L. ,  ELMORE, Steven, W. ,  SIPPY, Kevin, B. ,  TIETJE, Karin, R. ,  WENDT, Michael, D. ,  YAMAMOTO, Diane, M.

IPC: C07D495/04

CPC classification number: C07D403/06 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D487/14 ,  C07D491/04 ,  C07D491/14 ,  C07D495/04 ,  C07D495/14

Abstract: The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an alpha -1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are alpha -1 antagonist compositions and a method for antagonizing alpha -1 receptors and treating BPH.

Abstract translation: 本发明涉及式（I）化合物及其药学上可接受的盐，其中W是三环杂环体系; 其是α-1肾上腺素能拮抗剂，可用于治疗BPH; 还公开了α-1拮抗剂组合物和拮抗α-1受体并治疗BPH的方法。

公开(公告)号：WO2009134726A1

公开(公告)日：2009-11-05

申请号：PCT/US2009/041848

申请日：2009-04-27

Applicant: ABBOTT LABORATORIES ,  LIU, Huaqing ,  DRIZIN, Irene ,  COWART, Marlon, D. ,  ALTENBACH, Robert, J.

Inventor： LIU, Huaqing ,  DRIZIN, Irene ,  COWART, Marlon, D. ,  ALTENBACH, Robert, J.

IPC: C07D239/70 ,  C07D403/12 ,  C07D471/04 ,  C07D491/048 ,  C07D513/04 ,  C07D519/00 ,  A61K31/517 ,  A61K31/519

CPC classification number: C07D491/048 ,  C07D239/70 ,  C07D403/12 ,  C07D471/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present application describes substituted pyrimidine compounds of formula (I) wherein X, A 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , p, q, r, v, and w are defined in the specification, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions.

Abstract translation: 本申请描述了式（I）的取代嘧啶化合物，其中X，A1，R1，R2，R3，R4，R5，R6，R7，R8，R9，p，q，r，v和w在本说明书中定义 ，包含这些化合物的组合物，制备该化合物的方法，以及使用这些化合物和组合物治疗和预防疾病进展，病症和病症的方法。

公开(公告)号：WO2005016890A1

公开(公告)日：2005-02-24

申请号：PCT/US2004/025109

申请日：2004-08-04

Applicant: ABBOTT LABORATORIES ,  LEE, Chih-Hung ,  BAYBURT, Erol, K. ,  DIDOMENICO, Stanley, Jr. ,  DRIZIN, Irene ,  GOMTSYAN, Arthur, R. ,  KOENIG, John, R. ,  PENNER, Richard, J. ,  SCHMIDT, Robert, G., Jr. ,  TURNER, Sean, C. ,  WHITE, Tammie, K. ,  ZHENG, Guo Zhu

Inventor： BAYBURT, Erol, K. ,  DIDOMENICO, Stanley, Jr. ,  DRIZIN, Irene ,  GOMTSYAN, Arthur, R. ,  KOENIG, John, R. ,  PENNER, Richard, J. ,  SCHMIDT, Robert, G., Jr. ,  TURNER, Sean, C. ,  WHITE, Tammie, K. ,  ZHENG, Guo Zhu

IPC: C07D217/24

CPC classification number: C07D249/08 ,  C07D209/08 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D217/26 ,  C07D231/12 ,  C07D231/56 ,  C07D233/56 ,  C07D237/28 ,  C07D401/12 ,  C07D405/12

Abstract: Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Abstract translation: 式（I）化合物是可用于治疗疼痛，炎症性热痛觉过敏，尿失禁和膀胱过度活动的新型VR1拮抗剂。

公开(公告)号：WO2003070247A1

公开(公告)日：2003-08-28

申请号：PCT/US2003/004187

申请日：2003-02-11

Applicant: ABBOTT LABORATORIES

Inventor： LEE, Chih-Hung ,  BAYBURT, Erol, K. ,  DIDOMENICO, Stanley, Jr. ,  DRIZIN, Irene ,  GOMTSYAN, Arthur, R. ,  KOENIG, John, R. ,  PERNER, Richard, J. ,  SCHMIDT, Robert, G. ,  TURNER, Sean, C. ,  WHITE, Tammie, K. ,  ZHENG, Guo, Zhu

IPC: A61K31/502

CPC classification number: C07D249/08 ,  A61K31/404 ,  A61K31/416 ,  A61K31/47 ,  A61K31/472 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  C07D209/08 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D217/26 ,  C07D231/12 ,  C07D231/56 ,  C07D233/56 ,  C07D237/28 ,  C07D401/12 ,  C07D405/12

Abstract: Compounds of formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Abstract translation: 式（I）化合物是可用于治疗疼痛，炎症性热痛觉过敏，尿失禁和膀胱过度活动的新型VR1拮抗剂。

公开(公告)号：WO2011115813A1

公开(公告)日：2011-09-22

申请号：PCT/US2011/027905

申请日：2011-03-10

Applicant: ABBOTT LABORATORIES ,  DRIZIN, Irene ,  DOHERTY, George ,  BHATIA, Pramila A. ,  STEWART, Andrew O.

Inventor： DRIZIN, Irene ,  DOHERTY, George ,  BHATIA, Pramila A. ,  STEWART, Andrew O.

IPC: C07D211/76 ,  C07D401/06 ,  C07D401/08 ,  C07D401/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D403/06 ,  C07D471/08 ,  A61K31/4025 ,  A61K31/438 ,  A61K31/55 ,  A61K31/437 ,  A61K31/4545 ,  A61P25/00

CPC classification number: C07D211/76 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04

Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar 1 , n, R 1 , X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Abstract translation: 本申请涉及含有式（I）化合物的钙通道抑制剂，其中Ar1，n，R1，X和Y如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和病症的方法。

公开(公告)号：WO2010039947A1

公开(公告)日：2010-04-08

申请号：PCT/US2009/059215

申请日：2009-10-01

Applicant: ABBOTT LABORATORIES ,  BHATIA, Pramila, A. ,  DOHERTY, George, A. ,  DRIZIN, Irene ,  MACK, Helmut ,  PERNER, Richard, J. ,  STEWART, Andrew, O. ,  ZHANG, Qing Wei

Inventor： BHATIA, Pramila, A. ,  DOHERTY, George, A. ,  DRIZIN, Irene ,  MACK, Helmut ,  PERNER, Richard, J. ,  STEWART, Andrew, O. ,  ZHANG, Qing Wei

IPC: C07D211/76 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D207/27 ,  C07D207/48 ,  C07D487/10 ,  A61K31/395 ,  A61P25/04 ,  C07D413/14

CPC classification number: C07D487/10 ,  C07D207/27 ,  C07D207/48 ,  C07D209/52 ,  C07D211/76 ,  C07D211/96 ,  C07D241/08 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D409/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04

Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar 1 , Ar 2 , L 1 , L 2 , n, R 1 , R 4 , X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Abstract translation: 本申请涉及含有式（I）化合物的钙通道抑制剂，其中Ar1，Ar2，L1，L2，n，R1，R4，X和Y如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。

公开(公告)号：WO2009137492A1

公开(公告)日：2009-11-12

申请号：PCT/US2009/042860

申请日：2009-05-05

Applicant: ABBOTT LABORATORIES ,  LIU, Huaqing ,  DRIZIN, Irene ,  COWART, Marlon, D. ,  ALTENBACH, Robert, J.

Inventor： LIU, Huaqing ,  DRIZIN, Irene ,  COWART, Marlon, D. ,  ALTENBACH, Robert, J.

IPC: C07D495/04 ,  C07D498/04 ,  A61K31/519 ,  A61P29/00

CPC classification number: C07D498/04 ,  C07D495/04

Abstract: Heteroaryl-fused macrocyclic 2,4-diaminopyrimidine compounds of formula (I) wherein W, G 1 , G 2 , A 1 and R 1 are defined in the description, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Abstract translation: 其中W，G1，G2，A1和R1在说明书中定义的式（I）的杂芳基稠合的大环2,4-二氨基嘧啶化合物，包含这些化合物的组合物，制备该化合物的方法，以及治疗和预防进展的方法 使用这些化合物和组合物的疾病，病症和病症在本文中描述。

公开(公告)号：WO2008060767A3

公开(公告)日：2008-05-22

申请号：PCT/US2007/080133

申请日：2007-10-02

Applicant: ABBOTT LABORATORIES ,  ALTENBACH, Robert J ,  LIU, Huaqing ,  DRIZIN, Irene ,  COWART, Marlon D ,  WISHART, Neil ,  BABINSKI, David J ,  GREGG, Robert J ,  ESBENSHADE, Timothy A ,  HSIEH, Gin C ,  BRIONI, Jorge D ,  HONORE, Marie P ,  BLACK, Lawrence A ,  ZHAO, Chen ,  WAKEFIELD, Brian D.

Inventor： ALTENBACH, Robert J ,  LIU, Huaqing ,  DRIZIN, Irene ,  COWART, Marlon D ,  WISHART, Neil ,  BABINSKI, David J ,  GREGG, Robert J ,  ESBENSHADE, Timothy A ,  HSIEH, Gin C ,  BRIONI, Jorge D ,  HONORE, Marie P ,  BLACK, Lawrence A ,  ZHAO, Chen ,  WAKEFIELD, Brian D.

IPC: C07D491/04 ,  C07D493/04 ,  C07H17/04

Abstract: Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.